BGNE - BeiGene Ltd Stock Price, Fair Value and News

175.93USD+4.90 (+2.86%)Delayed as of 17 May 2024, 01:05 pm ET

Market Summary

USD175.93+4.90

Delayedas of 17 May 2024, 01:05 pm

2.86%

BGNE Alerts

1 major insider sales recently.

Big jump in Revenue (Y/Y)
Losses in recent quarter

BGNE Stock Price

View Fullscreen

BGNE RSI Chart

BGNE Valuation

Market Cap

232.5B

Price/Earnings (Trailing)

-296.42

Price/Sales (Trailing)

84.17

EV/EBITDA

-406.77

Price/Free Cashflow

-155.52

BGNE Price/Sales (Trailing)

BGNE Profitability

EBT Margin

-26.51%

Return on Equity

-23.34%

Return on Assets

-13.84%

Free Cashflow Yield

-0.64%

BGNE Fundamentals

BGNE Revenue

Revenue (TTM)

2.8B

Rev. Growth (Yr)

67.85%

Rev. Growth (Qtr)

18.48%

BGNE Earnings

Earnings (TTM)

-784.4M

Earnings Growth (Yr)

27.92%

Earnings Growth (Qtr)

31.67%

Breaking Down BGNE Revenue

52 Week Range

167.30245.74

(Low)(High)

Last 7 days

1.4%

Last 30 days

27.6%

Last 90 days

15.4%

Trailing 12 Months

-26.0%

How does BGNE drawdown profile look like?

BGNE Financial Health

Current Ratio

2.08

Debt/Equity

0.06

Debt/Cashflow

-4.53

BGNE Investor Care

Buy Backs (1Y)

0.23%

Diluted EPS (TTM)

-0.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.8B	0	0	0
2023	1.6B	1.8B	2.2B	2.5B
2022	877.0M	1.1B	1.2B	1.4B
2021	862.7M	947.0M	1.1B	1.2B
2020	402.4M	224.7M	265.7M	308.9M
2019	243.5M	434.1M	430.0M	428.2M
2018	281.1M	323.7M	157.7M	198.2M
2017	0	0	180.6M	238.4M
2016	8.1M	7.1M	64.9M	122.8M
2015	12.0M	10.9M	9.9M	8.8M
2014	0	0	0	13.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of BeiGene Ltd

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	oyler john	sold	-1,773,090	146	-12,084	chief executive officer
Apr 10, 2024	oyler john	sold	-3,977,860	148	-26,716	chief executive officer
Apr 09, 2024	oyler john	sold	-1,724,080	153	-11,200	chief executive officer
Mar 13, 2024	oyler john	sold	-2,189,650	177	-12,332	chief executive officer
Mar 12, 2024	oyler john	sold	-6,178,370	164	-37,668	chief executive officer
Mar 11, 2024	glazer donald w.	gifted	-	-	-82,020	-
Feb 29, 2024	wang julia aijun	sold	-66,330	167	-397	chief financial officer
Nov 30, 2023	wang xiaodong	sold	-	-	-172,372	-
Nov 30, 2023	wang xiaodong	gifted	-	-	-71,890	-
Nov 14, 2023	baker bros. advisors lp	sold	-198,550,000	180	-1,100,000	-

Which funds bought or sold BGNE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	LMR Partners LLP	added	451	2,344,860	2,964,220	0.03%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-98.52	-360,357	4,692	-%
May 15, 2024	UBS ASSET MANAGEMENT AMERICAS LLC	reduced	-40.07	-345,299	373,616	-%
May 15, 2024	Royal Bank of Canada	added	60.86	4,005,000	14,151,000	-%
May 15, 2024	Virtus ETF Advisers LLC	added	16.79	3,982	317,628	0.17%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-99.16	-2,116,550	15,483	-%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	new	-	1,094,730	1,094,730	0.06%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	reduced	-56.47	-9,544,170	5,786,430	0.60%
May 15, 2024	MARSHALL WACE, LLP	added	53.78	4,083,200	16,329,500	0.03%
May 15, 2024	Vestmark Advisory Solutions, Inc.	added	92.94	194,333	483,089	0.02%

Are Funds Buying or Selling BGNE?

Are funds buying BGNE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BGNE

No. of Funds

Unveiling BeiGene Ltd's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2024	capital international investors	7.6%	103,421,157	SC 13G/A
Feb 05, 2024	oyler john	5.2%	71,464,808	SC 13G/A
Nov 14, 2023	baker bros. advisors lp	10.2%	138,222,377	SC 13D/A
May 05, 2023	baker bros. advisors lp	11.2%	152,522,377	SC 13D/A
Feb 14, 2023	hhlr advisors, ltd.	10.9%	147,043,058	SC 13D/A
Feb 13, 2023	capital international investors	8.2%	110,215,170	SC 13G/A
Feb 10, 2023	invesco ltd.	2.6%	35,678,240	SC 13G/A
Feb 10, 2023	oyler john	5.1%	70,026,397	SC 13G/A
Aug 16, 2022	hhlr advisors, ltd.	10.9%	147,035,258	SC 13D/A
Feb 14, 2022	oyler john	5.1%	69,558,605	SC 13G/A

Recent SEC filings of BeiGene Ltd

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 23, 2024	8-K	Current Report
Apr 15, 2024	PRE 14A	PRE 14A
Apr 11, 2024	4	Insider Trading
Apr 09, 2024	144	Notice of Insider Sale Intent
Mar 26, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to BeiGene Ltd)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

BeiGene Ltd News

Latest updates

BeiGene Ltd Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	18.5%	751,652,000	634,409,000	781,308,000	595,261,000	447,801,000	380,095,000	387,628,000	341,572,000	306,626,000	213,979,000	206,440,000	149,992,000	605,872,000	100,100,000	91,080,000	65,635,000	52,059,000	56,892,000	50,141,000	243,346,000	77,833,000
Gross Profit	-	626,717,000	-	-	-	366,012,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	39.1%	888,065,000	638,284,000	915,276,000	913,976,000	819,059,000	562,242,000	825,985,000	780,971,000	749,913,000	620,812,000	668,765,000	624,830,000	535,705,000	585,012,000	531,217,000	424,512,000	425,815,000	444,929,000	362,407,000	329,179,000	251,588,000
S&GA Expenses	2.6%	427,427,000	416,547,000	364,421,000	395,034,000	328,499,000	328,984,000	322,892,000	331,403,000	294,573,000	306,501,000	269,227,000	232,289,000	182,106,000	208,209,000	160,837,000	124,049,000	107,081,000	143,354,000	105,002,000	82,248,000	57,645,000
R&D Expenses	-6.8%	460,638,000	493,987,000	453,259,000	422,764,000	408,584,000	446,023,000	426,363,000	378,207,000	389,915,000	430,485,000	351,937,000	356,091,000	320,726,000	355,537,000	349,070,000	285,968,000	304,302,000	283,259,000	236,968,000	228,760,000	178,351,000
EBITDA Margin	24.3%	-0.20	-0.27	-0.34	-0.85	-1.12	-1.30	-1.62	-1.80	-2.13	-1.20	-1.23	-1.39	-	-	-	-	-	-	-	-	-
Interest Expenses	-0.7%	16,160,000	16,274,000	26,649,000	15,070,000	16,016,000	18,219,000	12,759,000	11,431,000	10,071,000	-4,482,000	-2,230,000	-4,866,000	-4,179,000	-5,186,000	-614,000	1,108,000	6,690,000	-438,000	2,206,000	2,886,000	4,477,000
Income Taxes	-54.0%	7,724,000	16,781,000	13,925,000	13,674,000	11,492,000	14,370,000	6,318,000	8,141,000	13,949,000	11,463,000	5,036,000	-230,000	-4,630,000	18,741,000	-8,423,000	-1,475,000	1,554,000	7,561,000	-3,217,000	2,129,000	519,000
Earnings Before Taxes	30.6%	-243,426,000	-350,772,000	229,338,000	-367,463,000	-336,939,000	-430,965,000	-551,238,000	-557,585,000	-421,249,000	-586,804,000	-433,078,000	-480,571,000	61,865,000	-481,976,000	-435,040,000	-337,793,000	-363,385,000	-380,334,000	-311,877,000	-83,825,000	-167,550,000
EBT Margin	21.1%	-0.27	-0.34	-0.41	-0.93	-1.21	-1.38	-1.69	-1.87	-2.19	-1.22	-1.26	-1.41	-	-	-	-	-	-	-	-	-
Net Income	31.7%	-251,150,000	-367,553,000	215,413,000	-381,137,000	-348,431,000	-445,335,000	-557,556,000	-565,726,000	-435,198,000	-590,678,000	-438,114,000	-484,604,000	55,580,000	-472,745,000	-425,224,000	-336,318,000	-364,939,000	-388,061,000	-307,357,000	-85,570,000	-167,640,000
Net Income Margin	20.8%	-0.28	-0.36	-0.44	-0.96	-1.23	-1.42	-1.72	-1.90	-2.22	-1.24	-1.26	-1.40	-	-	-	-	-	-	-	-	-
Free Cashflow	-22.9%	-465,150,000	-378,597,000	-236,032,000	-415,358,000	-689,362,000	-439,549,000	-670,561,000	-430,249,000	-281,694,000	-622,818,000	-562,756,000	-458,797,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.4%	5,668	5,805	5,525	5,729	5,957	6,379	6,726	7,378	8,021	8,536	5,286	5,524	5,821	5,601	5,566	3,903	4,067	1,612	1,881	2,150	2,172
Current Assets	-7.0%	3,908	4,203	4,054	4,401	4,704	5,207	5,749	6,346	6,948	7,614	4,433	4,799	5,141	4,961	4,966	3,392	3,595	1,173	1,436	1,756	1,797
Cash Equivalents	-11.5%	2,807	3,172	3,067	3,410	3,539	3,870	4,197	4,531	4,347	4,376	1,383	1,776	1,902	1,390	1,464	1,345	1,957	621	857	919	764
Inventory	7.5%	447	416	317	321	297	282	291	262	246	243	151	118	73.00	89.00	36.00	33.00	29.00	29.00	38.00	49.00	13.00
Net PPE	7.1%	1,418	1,324	1,178	1,032	925	846	682	633	625	588	451	395	374	358	291	258	240	242	226	213	198
Goodwill	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00	0.00	0.00
Liabilities	1.7%	2,307	2,268	1,762	1,930	1,799	1,996	2,071	2,076	2,136	2,403	1,929	1,917	1,817	1,732	1,270	1,357	1,240	634	587	579	550
Current Liabilities	4.0%	1,882	1,810	1,283	1,405	1,255	1,469	1,411	1,398	1,376	1,600	1,304	1,242	1,113	1,075	646	551	452	310	266	272	239
Long Term Debt	-85.8%	199	1,403	1,478	207	1,417	1,443	1,480	1,241	202	202	201	195	193	184	152	131	82.00	83.00	104	84.00	77.00
LT Debt, Current	-83.1%	827	4,886	329	421	282	2,269	3,139	381	2,582	428	442	435	405	2,186	16.00	26.00	11.00	-	1.00	9.00	9.00
LT Debt, Non Current	-100.0%	-	1,403	1,478	207	1,417	1,443	1,480	1,241	202	202	201	195	193	184	152	131	82.00	83.00	104	84.00	77.00
Shareholder's Equity	-5.0%	3,360	3,537	3,763	3,799	4,157	4,383	4,655	5,197	5,774	6,133	3,252	3,526	3,927	3,803	4,297	2,546	2,827	940	1,294	1,571	1,623
Retained Earnings	-3.2%	-8,213	-7,962	-7,594	-7,809	-7,428	-7,080	-6,635	-5,971	-5,400	-5,076	-4,380	-3,966	-3,486	-3,552	-3,080	-2,654	-2,319	-1,955	-1,567	-1,260	-1,174
Additional Paid-In Capital	0.9%	11,705	11,599	11,503	11,752	11,645	11,541	11,452	11,357	11,268	11,191	7,725	7,561	7,487	7,415	7,368	5,200	5,138	2,926	2,861	2,814	2,777
Shares Outstanding	0.0%	1,360	1,360	1,353	1,376	1,363	1,356	1,338	1,336	1,332	1,206	1,196	1,194	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	10.00	15.00	16.00	16.00	17.00	14.00
Float	-	-	-	-	10,500	-	-	-	16,800	-	-	-	14,700	-	-	-	7,200	-	-	-	4,900	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-39.2%	-308	-221	-78.15	-293	-563	-318	-561	-379	-236	-507	-495	-420	125	-332	-346	-262	-341	-267	-265	-46.10	-171
Share Based Compensation	-4.6%	89.00	93.00	96.00	103	75.00	78.00	78.00	81.00	66.00	63.00	67.00	65.00	46.00	49.00	50.00	45.00	38.00	38.00	37.00	33.00	26.00
Cashflow From Investing	-235.3%	-209	-62.58	-186	68.00	241	39.00	169	659	210	109	-11.99	252	292	-86.92	-1,536	-429	-1,114	-23.89	214	192	172
Cashflow From Financing	-53.2%	162	347	-76.78	166	-19.87	-110	120	-17.58	-11.27	3,385	109	36.00	107	326	1,994	81.00	2,802	2.00	25.00	15.00	43.00
Buy Backs	-	-	-	363	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BGNE Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Total revenues	$ 751,652	$ 447,801
Gross profit	626,717	366,012
Operating expenses
Research and development	460,638	408,584
Selling, general and administrative	427,427	328,499
Amortization of intangible assets	0	187
Total operating expenses	888,065	737,270
Loss from operations	(261,348)	(371,258)
Interest income, net	16,160	16,016
Other income, net	1,762	18,303
Loss before income taxes	(243,426)	(336,939)
Income tax expense	7,724	11,492
Net loss	$ (251,150)	$ (348,431)
Net loss per share attributable to BeiGene, Ltd., basic (in dollars per share)	$ (0.19)	$ (0.26)
Net loss per share attributable to BeiGene, Ltd., diluted (in dollars per share)	$ (0.19)	$ (0.26)
Weighted-average shares outstanding—basic (in shares)	1,355,547,626	1,354,164,760
Weighted-average shares outstanding - diluted (in shares)	1,355,547,626	1,354,164,760
Net loss per American Depositary Share (ADS), basic (in dollars per share)	$ (2.41)	$ (3.34)
Net loss per American Depositary Share (ADS), diluted (in dollars per share)	$ (2.41)	$ (3.34)
Weighted-average ADSs outstanding - basic (in shares)	104,272,894	104,166,520
Weighted-average ADSs outstanding - diluted (in shares)	104,272,894	104,166,520
Product revenue, net
Revenues
Total revenues	$ 746,918	$ 410,291
Cost of sales - product	124,935	81,789
Collaboration revenue
Revenues
Total revenues	$ 4,734	$ 37,510

BGNE Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands	Mar. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)
Current assets:
Cash and cash equivalents	$ 2,793,370	$ 3,171,800
Short-term investments	0	2,600
Accounts receivable, net	435,294	358,027
Inventories, net	447,345	416,122
Prepaid expenses and other current assets	231,741	254,865
Total current assets	3,907,750	4,203,414
Property, plant and equipment, net	1,417,992	1,324,154
Operating lease right-of-use assets	87,747	95,207
Intangible assets, net	55,171	57,138
Other non-current assets	199,021	125,362
Total non-current assets	1,759,931	1,601,861
Total assets	5,667,681	5,805,275
Current liabilities:
Accounts payable	356,575	315,111
Accrued expenses and other payables	569,438	693,731
Tax payable	27,324	22,951
Operating lease liabilities, current portion	19,401	21,950
Research and development cost share liability, current portion	81,986	68,004
Short-term debt	826,965	688,366
Total current liabilities	1,881,689	1,810,113
Non-current liabilities:
Long-term bank loans	199,027	197,618
Operating lease liabilities, non-current portion	17,722	22,251
Deferred tax liabilities	16,437	16,494
Research and development cost share liability, non-current portion	143,544	170,662
Other long-term liabilities	48,901	50,810
Total non-current liabilities	425,631	457,835
Total liabilities	2,307,320	2,267,948
Commitments and contingencies
Shareholders’ equity:
Ordinary shares, $0.0001 par value per share; 9,500,000,000 shares authorized; 1,359,524,369 and 1,359,513,224 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	136	135
Additional paid-in capital	11,705,069	11,598,688
Accumulated other comprehensive loss	(131,644)	(99,446)
Accumulated deficit	(8,213,200)	(7,962,050)
Total shareholders’ equity	3,360,361	3,537,327
Total liabilities and shareholders’ equity	$ 5,667,681	$ 5,805,275

About BeiGene Ltd

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company is also developing Zanubrutinib to treat B-cell malignancies; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Ociperlimab for treating solid tumors, cervical cancer, and NSCLC; Surzebiclimab, BGB-A445, BGB-15025, Lifirafenib, BGB-24714, and BGB-B167 to treat solid tumors; BGB-10188 for treating solid tumors, B-cell lymphoid malignancies, and B-cell malignancies; BGB-11417 to treat R/R chronic lymphocytic leukemia/ small lymphocytic lymphoma, R/R mantle cell lymphoma, Mature B-cell malignancies, Myeloid malignancies, and R/R multiple myeloma; BGB-16673 for B-cell malignancies; and BGB-23339 for Inflammation and immunology. The company has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., Enlivex Therapeutics Ltd., Chime Biologics Limited, and Nanjing Leads Biolabs Co., Ltd. BeiGene, Ltd. was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

CEO	Mr. John V. Oyler
WEBSITE	beigene.com
INDUSTRY	Biotechnology
EMPLOYEES	10000

BeiGene Ltd Frequently Asked Questions

What is the ticker symbol for BeiGene Ltd? What does BGNE stand for in stocks?

BGNE is the stock ticker symbol of BeiGene Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BeiGene Ltd (BGNE)?

As of Thu May 16 2024, market cap of BeiGene Ltd is 232.52 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BGNE stock?

You can check BGNE's fair value in chart for subscribers.

What is the fair value of BGNE stock?

You can check BGNE's fair value in chart for subscribers. The fair value of BeiGene Ltd is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BeiGene Ltd is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BGNE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BeiGene Ltd a good stock to buy?

The fair value guage provides a quick view whether BGNE is over valued or under valued. Whether BeiGene Ltd is cheap or expensive depends on the assumptions which impact BeiGene Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BGNE.

What is BeiGene Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, BGNE's PE ratio (Price to Earnings) is -296.42 and Price to Sales (PS) ratio is 84.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BGNE PE ratio will change depending on the future growth rate expectations of investors.